Allarity Therapeutics 관리

관리 기준 확인 1/4

Allarity Therapeutics CEO는 Thomas Jensen, Jan2004 에 임명되었습니다 의 임기는 20.83 년입니다. 는 $ 1.25 가치에 해당하는 회사 주식의 0% 직접 소유합니다. 1.25. 경영진과 이사회의 평균 재임 기간은 각각 0.2 년과 2.1 년입니다.

주요 정보

Thomas Jensen

최고 경영자

US$24.7k

총 보상

CEO 급여 비율	n/a
CEO 임기	20.8yrs
CEO 소유권	0.00007%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	2.1yrs

최근 관리 업데이트

Recent updates

CEO

Thomas Jensen (46 yo)

20.8yrs

테뉴어

US$24,720

보상

Mr. Thomas H. Jensen is Co-Founder of Allarity Therapeutics, Inc. and serves as its Director since July 7, 2022. He is Chief Executive Officer since December 08, 2023 at Allarity Therapeutics, Inc. and ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Jensen	Founder	20.8yrs	US$24.72k	0.000070% $ 1.2
Steen Knudsen	Founder & Chief Scientific Officer	20.8yrs	US$266.22k	0.000070% $ 1.2
Jeremy Graff	President & Chief Development Officer	less than a year	데이터 없음	데이터 없음
Peter Jensen	Co-Founder	no data	US$128.02k	데이터 없음
Alexander Epshinsky	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Jose Iglesias	Consultant Chief Medical Officer	less than a year	데이터 없음	데이터 없음

0.2yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: ALLR 의 관리팀은 경험 (평균 재직 기간 0.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Jensen	Founder	2.3yrs	US$24.72k	0.000070% $ 1.2
Daniel Von Hoff	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gerald McLaughlin	Independent Chairman of the Board	2.1yrs	US$107.38k	0.000070% $ 1.2
Joyce O'Shaughnessy	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mansoor Mirza	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joseph Vazzano	Independent Director	1.3yrs	US$29.17k	데이터 없음
Laura Benjamin	Independent Director	1.3yrs	US$27.71k	데이터 없음
Ursula Matulonis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Roberto Pili	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: ALLR 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Allarity Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Allarity Therapeutics, Inc. Announces Management Appointments

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Board Changes

Recent updates

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics, Inc. Announces Management Appointments

Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics appoints interim CEO, CFO

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령